The "EXTEND" Study: A Randomized, Double-Blind, Parallel-Group, Phase III b, Multi-Centre Study Evaluating Extended Prophylactic Treatment With Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events in Patients Undergoing Elective Hip Replacement or Hip Fracture Surgery
Latest Information Update: 30 Aug 2021
At a glance
- Drugs Melagatran (Primary) ; Ximelagatran (Primary) ; Enoxaparin sodium
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms EXTEND
- Sponsors AstraZeneca
- 30 Aug 2021 This trial has been completed in Spain (End Date: 01 Aug 2006), according to European Clinical Trials Database record.
- 01 Mar 2009 Safety results published in Thrombosis Research.
- 26 Nov 2005 New trial record.